{"id":"extended-release-torsemide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"5-10%","effect":"Dehydration"},{"rate":"5-10%","effect":"Electrolyte imbalance"}]},"_chembl":{"chemblId":"CHEMBL1148","moleculeType":"Small molecule","molecularWeight":"348.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to increased excretion of sodium, chloride, and water, resulting in decreased blood volume and pressure. Torsemide has a longer duration of action compared to other loop diuretics due to its extended release formulation.","oneSentence":"Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle in the kidneys.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:11.581Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Edema"}]},"trialDetails":[{"nctId":"NCT06206512","phase":"PHASE2","title":"Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2024-06-15","conditions":"Heart Failure, Overactive Bladder, Incontinence","enrollment":24},{"nctId":"NCT06995144","phase":"PHASE4","title":"Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-05-28","conditions":"Heart Failure, Edema, Pulmonary Congestion","enrollment":20},{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT06708611","phase":"PHASE4","title":"A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-01-15","conditions":"Heart Failure","enrollment":5},{"nctId":"NCT06176794","phase":"PHASE2","title":"Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal","status":"TERMINATED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2024-11-15","conditions":"Heart Failure","enrollment":1},{"nctId":"NCT03509545","phase":"PHASE1","title":"Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2021-06-30","conditions":"Body Weight Changes","enrollment":20},{"nctId":"NCT03214874","phase":"PHASE1","title":"Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2017-06-19","conditions":"Congestive Heart Failure, Chronic Kidney Diseases","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Extended release torsemide","genericName":"Extended release torsemide","companyName":"Sarfez Pharmaceuticals, Inc.","companyId":"sarfez-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle in the kidneys. Used for Hypertension, Edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}